"The funds raised under the SPP will be used to fund the immediate required production to fulfil current and ongoing orders for the Company’s cannabinoid-based medicines including CannEpil®, CogniCann® and MP100 in Australia, Europe and Latin America, the ongoing operating expenses of the Company and general working capital."
No money to spent on building the Malta facility which according to previous company announcements by MXC was meant to be built & operational by now. Infact not a single sod has been turned.
MXC Price at posting:
2.7¢ Sentiment: Hold Disclosure: Held
